Response to intravenous racemic ketamine after switch from intranasal (S)‐ketamine on symptoms of treatment‐resistant depression and post‐traumatic stress disorder in Veterans: A retrospective case series
| Autor: | Sean Bentley, Hewa Artin, Eamonn Mehaffey, Fred Liu, Kevin Sojourner, Andrew Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra, Dhakshin Ramanathan |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
ketamine
Depression Major Depressive Disorder (S)-ketamine Clinical Trials and Supportive Activities Evaluation of treatments and therapeutic interventions Pharmacology and Pharmaceutical Sciences Post-Traumatic Stress Disorder (PTSD) Serious Mental Illness Brain Disorders Mental Health Clinical Research 6.1 Pharmaceuticals Post-Traumatic Humans Pharmacology (medical) Pharmacology & Pharmacy Retrospective Studies Stress Disorders Veterans |
| Zdroj: | Pharmacotherapy, vol 42, iss 3 |
| ISSN: | 1875-9114 0277-0008 |
| DOI: | 10.1002/phar.2664 |
| Popis: | BackgroundRacemic (R,S)-ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)-ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment-resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of ketamine. However, recent meta-analyses have suggested that IV racemic ketamine may be more potent than IN-(S)-ketamine.MethodsWe retrospectively analyzed clinical outcomes in 15 Veterans with comorbid TRD and post-traumatic stress disorder (PTSD) who underwent ketamine treatment at the VA San Diego Neuromodulation Clinic. All Veterans included in this analysis were given at least 6 intranasal (IN)-(S)-ketamine treatments prior to switching to treatment with IV racemic ketamine.ResultsVeterans receiving ketamine treatment ( across both IN-(S)-ketamine and IV-(R,S)-ketamine) showed significant reductions in both the Patient Health Questionnaire-9 (PHQ-9), a self-report scale measuring depression symptoms (rm ANOVA F(14,42)=12.6, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text